Novo Nordisk extended a four-day winning streak on Friday, adding 5.18 percent to close at $88.08 apiece as investors cheered ...

Investing.com - The S&P 500 slumped Friday, ending the week with a loss as soft data flagging worries about the economy triggered a sea of red of across stock. At 4:00 p.m. ET, the 30-stock Dow Jones ...

This can be found among the Granolas, a group of 11 European multinationals, selected by US bank Goldman Sachs, which is made ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

GLP-1 drugs like Wegovy and Ozempic, which are made by Novo Nordisk (NVO), have seen a shortage since 2022 amid rising demand. While that shortage was in effect, it allowed compounders - drug makers ...

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Approval Drop. In this article, we ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

It should be noted that Hims and Hers stock had jumped 43% in the week prior to the announcement, which has been attributed to the acquisition of Tybre Labs and a controversial Super Bowl ad.

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...